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Abstract: Bilastine is a second generation antihistamine indicated for the treatment of seasonal 
or perennial allergic rhinoconjunctivitis and chronic urticaria with a daily dose of 20 mg, in 
adults and children over 12 years of age. The efficacy of bilastine has been shown to be similar 
to that of the comparator drugs for the control of the nasal and nonnasal symptoms of allergic 
rhinoconjunctivitis, while also showing a subjective improvement in the quality of life and in overall 
clinical impression. For chronic urticaria the symptoms (itching and the development of papules) 
lessens from the second day of treatment onwards, in a similar way to other antihistamines used 
as comparators. Bilastine should not be administered at meal times to avoid interference with the 
absorption process. It is not distributed to the central nervous system, is scarcely metabolized, and 
elimination is through the kidneys and feces, with a 14-hour elimination half-life. It has no effect on 
cytochrome P450. During clinical development, bilastine was shown to be a drug that is adequately 
tolerated, with a similar effect to placebo with regard to drowsiness and changes in heart rate. In 
relation to its use, headaches were the most frequent adverse effect to be reported. No cardiotoxic 
effects have been observed, and the therapeutic dose does not alter the state of alertness.
Keywords: bilastine, allergic rhinoconjunctivitis, chronic urticaria, second generation 
antihistamine, drowsiness, CYP450
Bilastine
Bilastine is a recently marketed, orally administered antihistamine for the treatment of 
allergic rhinoconjunctivitis and chronic urticaria in adults and adolescents. The treatment 
of both disorders with antihistamines has been clearly established.1 Second generation 
antihistamines have surpassed first generation ones due to their improved tolerance, 
primarily based on their lack of anticholinergic effects and lower risk of cardiotoxicity. 
However, second generation antihistamines are able to cross the blood-brain barrier and, 
therefore, can induce drowsiness. Likewise, many of these antihistamines are metabolized 
by cytochrome P450 enzymes, and thus can possibly interact with other drugs. As discussed 
below, these characteristics have been addressed and modified with bilastine. The aim 
of this paper is to assess the present situation of the aforementioned antihistamine for the 
treatment of chronic urticaria and allergic rhinoconjunctivitis, through an evaluation of 
the results published regarding the efficacy and safety of this new drug.
Pharmacodynamics
Bilastine, or 2-[4-[2-[4-[1-(2-ethoxyethyl) benzimidazol-2-yl] piperidin-1-yl] ethyl] 
phenyl]-2-methylpropionic acid (Figure 1), is a molecule with a molecular weight 
of 463.6 Daltons. Based on bilastine’s structure, it is classified within the group 
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of new antihistamines, as a second generation original 
molecule.
Bilastine is highly selective for histamine receptor (H1) 
binding, without inhibiting other receptors (muscarinic, 
adrenergic, serotonergic, other histamine receptors, brady-
kinin, leukotriene d4, or calcium). It shows great affinity for 
the H1, comparable to other antihistamines, such as astemi-
zole or diphenhydramine, and a three and five fold greater 
affinity than fexofenadine and cetirizine, respectively.2 The 
inhibition of this receptor blocking is dose dependent. The 
antimuscarinic effect was specifically studied in preclinical 
trials and in healthy volunteers alike; this effect was not 
observed in the cellular models. In humans, no change was 
observed in pupillary reactivity following treatment with dif-
ferent dose levels of bilastine (20, 40, and 80 mg/day) over 
a 7-day period.3 It can therefore be concluded that bilastine 
does not present undesirable anticholinergic effects associ-
ated with first generation antihistamines.
In different murine models, bilastine antagonizes the 
effect of histamine in a concentration-dependent manner 
(inhibiting increased capillary permeability, decreased 
microvascular extravasation, and decreased bronchospasm), 
with a similar potency to fexofenadine and greater than that of 
cetirizine. The antihistaminic effect of bilastine had a longer 
lasting duration than observed for cetirizine.4
Inhibition of the release of histamine, interleukin (IL)-4, 
and tumor necrosis factor-α was observed in peripheral blood 
mast cells and granulocytes following bilastine treatment.5
In a phase I study on healthy volunteers in which dose 
levels of 2.5 and 50 mg were evaluated, a reduction in 
histamine induced flare and wheal was observed, similar to 
that observed with cetirizine, although the higher dose levels 
for bilastine, (20 and 50 mg) meant faster results.6
Pharmacokinetics
Bilastine is marketed as tablets and its pharmacokinetic 
properties were evaluated in preclinical and clinical trials, 
several of which were phase I trials (see Table 1). The phar-
macokinetic parameters of bilastine are shown in Table 1.
Following oral administration, bilastine is rapidly 
absorbed, reaching a maximum concentration (C
max
) in 1 
to 1.5 hours. Absorption is a first order process, observing 
dose linearity in the range from 2.5 to 220 mg, for single 
and multi doses alike, with no sign of accumulation after 
14 days of treatment.7,8 This is a rapid process, with an 
absorption constant of 1.5 h-1.7 The oral administration of 
20 mg, considered to be the therapeutic dose, achieved a 
mean maximum concentration of 220 ng/ml 1.3 hours after 
administration, with subsequent biexponential elimination.
Bilastine has a bioavailability of 60%. It is a substrate 
of the membrane transporters present in the intestinal lumen 
cells, the P glycoprotein, and the organic anion-transporting 
polypeptide. The P glycoprotein is responsible for incomplete 
bioavailability, being an efflux protein, while the organic 
anion-transporting polypeptide facilitates absorption. Both 
transporters are present in the luminal membrane of the 
duodenum, indicating a powerful interaction between them, 
working in opposite directions. Both are liable to interactions 
when administered with fruit juices and some drugs.9
Bioavailability is lessened when administered together with 
food rich in fats and with substances that modify the membrane 
transporter activity. In a study involving healthy volunteers, 
a 30% reduction in bioavailability was observed when 
administered together with a high fat meal and a 25% reduction 
when the meal had standard fat content.10,11 Grapefruit juice 
in particular caused a 30% reduction in bioavailability.10,11
Bilastine has a two compartment distribution, with 
an apparent volume of distribution of 1.29 l/kg. It binds 
to plasma proteins in a proportion from 84% to 90%. 
N
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Figure 1 Chemical structure of bilastine.
Table 1 Pharmacokinetic parameters of bilastine from single 
dose studies11,18,23,27
Healthy volunteers
Dose (mg)/route 20/oral
Cmax (ng/mL) 182.4–256.56
Tmax (hour) 1.11–1.56
AUC0-t (ng/mL*h) 876–1289.2
F oral (%) 61
T1/2 alpha (hour) 2.1
T1/2 beta (hour) 14.5
vc (L) 59.2
vp (L) 30.2
Cl (L/hour) 18.1
Abbreviations: AUC0-t, area under the plasma drug concentration-time curve 
between 0 and t; Cmax, maximum plasma concentration; CL, clearance; t, time; Tmax, 
time to reach Cmax; F, bioavailability; t1/2alpha, half-life of distribution; t1/2beta, half-
life of elimination; vc, volume of distribution in central compartment; vp, volume of 
distribution in peripheral compartment.
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In studies on animals with radiolabeled bilastine, the drug 
was distributed in the gastrointestinal tract and liver, without 
reaching the brain.12
Bilastine is scarcely metabolized, and is excreted 
unchanged through the kidneys and feces. A mass balance 
study showed that 33% of bilastine was excreted in the urine 
and 67% in the feces.13 A study with hepatocyte cultures 
and liver microsomes demonstrated the non-existence 
of cytochrome P450 mediated metabolization, nor was 
any inhibiting or inducing effect observed with regard to 
this same enzyme.7 This lack of inhibition is one of the 
characteristics that makes bilastine a compound of interest, 
according to the recommendations published by a group of 
experts on the treatment of allergic rhinitis;1 96% of the dose 
administered was eliminated in 24 hours and at 72 hours it 
was completely eliminated from urine, with an elimination 
half-life of around 14 hours. Renal function impairment did 
not significantly alter the pharmacokinetics of bilastine10 
although an increase in the plasma concentrations of the 
antihistamine was observed. In general, this suggests that 
there is no need to modify the dose in the event of renal 
impairment, although this precaution should be taken into 
account in situations in which the concentrations of bilastine 
may be increased in the blood as a result of the concomitant 
administration of P glycoprotein inhibitors, as was observed 
with ketoconazole.14
No evaluation of bilastine administration to patients 
with liver damage has been made, although given the fact 
that bilastine does not metabolize, no pharmacokinetic 
modification or the need for dosage adjustment whatsoever 
is to be expected for these patients.
No differences in bilastine pharmacokinetics have been 
observed with regard to sex or age, except for the highest 
maximum plasma concentration (C
max
) values in young 
women (18–35 years). In a population pharmacokinetics 
analysis, no influence of various covariables was observed 
(age, weight, height, sex, heart rate, serum albumin, 
creatinine, bilirubin, liver transaminases, alkaline phosphates, 
or urea).7
Based on data from adults, it was estimated that the dose 
for children aged 2 to 12 years should be 10 mg per day and 
5 mg per day for children under the age of two,15 although 
studies are currently being conducted to confirm this dose.
The possibility of bilastine interacting with food and 
other drugs was previously evaluated. As mentioned, 
grapefruit juice reduces the bioavailability of bilastine.10,11 
The mechanism responsible for this interaction could be 
the inhibition of the organic anion-transporting polypeptide 
membrane transporter, which facilitates the absorption of 
some drugs.9 This effect on the transporter could be avoided 
by taking bilastine either one hour before or two hours after 
the intake of juices or food. Some substrate drugs or inhibitors 
of this transporter, such as ritonavir or rifampicin, could 
reduce bilastine plasma concentrations,16 although this point 
has not been specifically evaluated.
No effect of bilastine has been observed on the 
pharmacokinetics of ketoconazole in healthy volunteers.14 
On the other hand, exposure to bilastine increased as a result 
of coadministration with ketoconazole, which doubled the 
exposure of the antihistamine, probably due to the inhibitor 
effect on the membrane transporters, such as P glycoprotein, 
in the intestinal lumen without modifying the hepatic 
clearance. 17
No interaction was observed with the central nervous 
system depressors, such as lorazepam18 or alcohol.19
Pharmacokinetics/pharmacodynamics
When jointly evaluating the pharmacokinetic and 
pharmacodynamic data, it was concluded that bilastine is 
characterized by two compartment kinetics, with a rapid 
absorption phase and a maximum response 4 hours after 
administration. The pharmacodynamics of the disappearance 
of the wheal or flare was fitted to an indirect response model 
to define a concentration that produces a 50% inhibition 
(IC
50
) of 5.15 ng/ml and 1.25 ng/ml, respectively. With 
a daily administration of 20 mg of bilastine to adults, the 
plasma concentrations remain above these values for 20 
and 24 hours, respectively, indicating that a once a day 
administration is adequate.7 In a simulation performed for 
children aged from 2 to 12, the 10 mg dose was sufficient to 
maintain the plasma concentrations above this value for the 
entire administration interval.15
Efficacy
Efficacy evaluation of bilastine from clinical investigation 
is shown in Table 2.
The onset of action and the duration of the antihistaminic 
effect are both decisive factors in selecting an antihistamine. 
Along these lines, an evaluation was made of the effects of 
bilastine on allergen-induced nasal and eye symptoms in 
75 patients allergic to pollen. The patients were exposed to 
controlled concentrations of pollen using a standard allergy 
provocation method (Vienna Challenge Chamber).20 The 
subjects underwent two provocation tests with pollen on two 
consecutive days, for 6 hours on the first day and for 4 hours 
on the second day. The nasal symptoms were assessed every 
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15 minutes. Four of these symptoms (rhinorrhea, nasal 
congestion, sneezing, and nasal itching) were considered 
to be the principal study variables. The treatments studied 
were 20 mg of bilastine, 10 mg of cetirizine, 120 mg of 
fexofenadine, or a placebo, administered 2 hours after the 
first provocation. In this study, onset of action was observed 
at around 1 hour for bilastine and cetirizine, with duration 
of action of at least 26 hours. The duration of action of 
fexofenadine was considered shorter, given the fact that it 
was less effective on the second day of the study.20 A similar 
study compared the effect of 20 and 50 mg of bilastine 
to 10 mg of cetirizine with respect to the inhibition of 
cutaneous wheal and flare following a skin prick test at 
different times in relation to the drug administration. The 
response was similar for 20 mg of bilastine and 10 mg of 
cetirizine at the different measurement points, with the 
exception of the analysis obtained 1.5 hours following 
administration, which indicated that bilastine had a faster 
onset of action. The administration of 50 mg of bilastine 
prolonged the duration of the antihistaminic effect.21 In a 
study on healthy volunteers, the results observed showed 
the existence of a certain dose dependency in regards to the 
inhibition of wheals following subcutaneously administered 
histamine.3
Clinical studies
Allergic rhinoconjunctivitis 
(seasonal and perennial)
H1 antihistamines are first line drugs for the treatment 
of allergic rhinoconjunctivitis. Allergic rhinitis is one of 
the most common chronic diseases in the world, with an 
estimated prevalence of 10%–25%.22 The most frequent 
Table 2 Bilastine efficacy determined during clinical investigation
Author Study design Primary endpoint Efficacy
Bachert 
et al29
Seasonal allergic rhinitis (n = 721). 
Randomized, double blind, placebo- 
controlled, parallel group, 14 days, 
bilastine 20 mg, desloratadine 5 mg,  
and placebo
Mean AUC of the reflective TSS from 
day 0 to day 14, composed of NSS 
(congestion, rhinorrhea, sneezing, and 
itch) and NNSS (ocular itching, burning, 
redness, sensation of foreign body in eye, 
tearing, and itching of ears and/or palate)
NSD between active treatments 
but significantly more effective 
than placebo in reducing AUC- 
TSS over the entire treatment 
period, improving the NSS, NNSS, 
rhinitis-associated discomfort, 
rhinoconjunctivitis, and quality of life
Kuna 
et al30
Seasonal allergic rhinitis (n = 681). 
Randomized, double blind, placebo- 
controlled, parallel group, 14 days, 
bilastine 20 mg, cetirizine 10 mg,  
and placebo
Mean AUC of the reflective TSS from day 
0 to day 14, calculated daily as the sum of 
four nasal (rhinorrhea, congestion, itching 
and sneezing) and three nonnasal, ocular 
symptoms (tearing, redness and itching)
NSD between active treatments 
but significantly more effective than 
placebo in reducing AUC-TSS over 
the entire treatment period
Zuberbier 
et al37
Chronic idiopathic urticaria (n = 525). 
Double-blind, randomized, placebo- 
controlled, 28 days, bilastine 20 mg, 
levocetirizine 5 mg, and placebo
TSS was calculated as the sum of scores 
for pruritus, number of wheals, and the 
maximum wheal size recorded in the 
patients’ diaries each day, from day 
0 to day 28
NSD between active treatments 
more effective than placebo to 
improve Dermatology Life Quality 
Index, general discomfort, and 
sleep disruption. Treatment with 
bilastine and levocetirizine reduced 
instantaneous and reflective TSS 
in a similar manner
Sastre 
et al31
Perennial allergic rhinitis (n = 650). 
Randomized, placebo-controlled, 
double-blind, parallel-group, 4 weeks, 
bilastine 20 mg, cetirizine 10 mg, 
and placebo
Mean AUC of the reflective TSS from 
day 0 to day 28: total of 6 reflective or 
instantaneous symptom scores (T6SS) as 
well as T4NSS (rhinorrhea, nasal itching, 
sneezing, nasal congestion) and T2OSS 
(ocular redness, tearing)
Statistically significant differences 
existed between active treatments 
and placebo in the mean AUC of 
T6SS and T4NSS (not in South 
Africa patients). Bilastine 20 mg, 
but not cetirizine 10 mg, reached 
maximum response in a statistically 
significant shorter time than placebo
Horak 
et al20
Asymptomatic patients (n = 75). 
Double-blind cross-over, allergen- 
induced symptoms in the vienna 
Challenge, single dose, bilastine 20 mg, 
cetirizine 10 mg, fexofenadine 120 mg
Reflective NSS in patients challenged 
with allergen for 6 hours
Bilastine and cetirizine had a rapid 
onset of action, within 1 hour, 
duration of action greater than 
26 hours. Fexofenadine was less 
effective on day two
Abbreviations: AUC-TSS, the area under curve of total symptom scores; NNSS, nonnasal symptom scores; NSD, no significant differences; NSS, nasal symptom scores; 
T2OSS, total 2-ocular symptom scores; T4NSS, reflective and instantaneous total 4-nasal symptom scores; T6SS, total 6-symptom scores.
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symptoms of allergic rhinitis are nasal itching, sneezing fits, 
rhinorrhea, and nasal obstruction.23 Patients with allergic 
rhinitis show a reduced quality of life24 due to the inherent 
symptoms of rhinitis and the physiopathology, which can 
result in sleep disorders.25
The nasal response to allergen stimulation provokes all 
the symptoms characteristic of allergic rhinitis. This response 
comprises two phases: the immediate response is observed 
20 minutes after contact with the allergen and can continue 
for up to hours afterwards. This is primarily the result of mast 
cell degranulation. This phase is characterized by itching, 
sneezing, and rhinorrhea. Mast cells release chemotactic 
substances and cytokines that are able to attract other cells 
to the inflammatory focus, including eosinophils. This gives 
rise to the late phase of the allergic response (48 hours 
later), which comprises the cellular response. The principal 
response in this phase is nasal obstruction.26
Histamine is one of the substances released by the mast 
cells and basophils. This amine is released in a few seconds in 
E immunoglobulin (IgE) mediated hypersensitivity reactions. 
A minute after the nasal allergic stimulation, the histamine 
released reaches its maximum concentration. Ten minutes 
after this peak, there is an abrupt drop in concentration.27 
Histamine induces increased chemotaxis of eosinophils, 
increased cytokine (IL-1β, IL-6, IL-4, and IL-5) release, 
increased vascular cell adhesion molecule (VCAM)-1 expres-
sion and activation of nuclear factor (NF)-κβ. Histamine is 
responsible for the characteristic symptomatology of allergic 
rhinitis, including nasal obstruction.
H1 antihistamines can act through different routes of action; 
they counteract the effects of histamine on the H1 receptors 
and they are also able to inhibit the release from mast cells 
and basophils, which contribute to the late phase of the allergic 
response.28 Bilastine is a highly selective antihistamine, with 
moderate to high H1 receptor affinity. Furthermore, in vitro 
studies have shown anti-inflammatory activity by inhibiting the 
release of histamine, IL-4, and tumor necrosis factor (TNF)-α, 
and also by inducing the release of different stimulants.5
The efficacy of bilastine in allergic rhinoconjunctivitis 
has been confirmed in several studies comparing it to either 
a placebo or to other antihistamines.
Bachert et al conducted a multicenter study to assess clinical 
efficacy through the rating of nasal and nonnasal symptoms 
at the start and after 14 days of treatment, and the safety of 
20 mg of bilastine compared to 5 mg of desloratadine and 
placebo in patients with seasonal allergic rhinitis (n = 721). A 
significant decrease was observed in the nasal and nonnasal 
symptoms of patients treated with both drugs in relation to the 
placebo. Along these same lines, a reduction in the patient-rated 
discomfort score and an improvement in the investigator’s 
overall clinical impression were observed. However, no 
differences were found between bilastine and desloratadine.29
A further study compared the administration of 20 mg of 
bilastine to 10 mg of cetirizine or placebo in patients with 
seasonal rhinitis, finding statistically significant differences 
in the improvement of the nasal symptoms in the group 
administered with bilastine (-43.8% after 7 days and -48.5% 
after 14 days) and cetirizine (-40.2% after 7 days, and -50.6% 
after 14 days) in relation to the placebo group (P , 0.001), 
yet without any differences between treatment groups.30
Daily treatment with 2 mg of bilastine was effective for 
the treatment of perennial allergic rhinitis, a disease which 
affects a high percentage of the population (10%–15%). An 
assessment was made of the nasal symptoms (rhinorrhea, 
sneezing, congestion, itching) and eye symptoms (redness, 
tears) compared to the placebo; the results showed bilastine 
and cetirizine were similar in Europe and superior in 
Argentina, achieving an approximate 34% reduction in 
nasal symptoms after 28 days of treatment.31
Bartra et al reviewed clinical trials conducted with bilas-
tine in order to assess its effect on eye symptoms of allergic 
rhinoconjunctivitis (itching, redness, and tearing). The clinical 
test results showed bilastine to be as effective as the com-
parator drugs for controlling the eye symptoms in seasonal 
allergic rhinitis.32
Likewise, an evaluation of the effects of bilastine on 
nasal obstruction in allergic rhinitis was performed. The 
efficacy of 20 mg of bilastine for controlling this symptom 
was tested and was determined to be along the same lines as 
that observed with active comparators (desloratadine 5 mg 
and cetirizine 10 mg).23
The quality of life variable was also recently analyzed 
separately, given the fact that it has been studied as a secondary 
objective in three clinical studies on allergic rhinitis, by means 
of the Rhinoconjunctivitis Quality of Life Questionnaire 
(RQLQ) questionnaire on a total number of 2335 patients and 
in chronic urticaria through the Dermatology Life Quality 
Index (DLQI) questionnaire on a total of 525 patients, 
compared to levocetirizine and placebo.33 The results are 
parallel to the efficacy results observed in the clinical trials.
Chronic urticaria
Chronic urticaria significantly affects patients’ quality 
of life. It is characterized by the appearance of pruritic 
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erythematous papules. The papules have a duration of less 
than 24 hours in which they may appear daily or more than 
once a week for 6 weeks. In 50% of cases, this is associated 
with the appearance of angioedema.34
The clinical guidelines for the treatment of chronic 
urticaria suggest increasing the normal dosage of the 
antihistamine by up to 4-fold, if the normal therapeutic dosing 
is not effective.35 However, in the literature, there are no 
randomized, double blind trials that study whether there is 
any difference in efficacy between the therapeutic doses and 
higher doses for controlling chronic urticaria. In this respect, 
preliminary data with bilastine are available, such as the data 
obtained in a phase I double blind single dose clinical trial 
with four crossover periods on 21 volunteers administered 
with either placebo, 10 mg of cetirizine, or 2.5, 5, 10, or 
50 mg of bilastine. An evaluation of the relationship between 
the dose of bilastine and the inhibition of the cutaneous 
response to histamine (measured by wheal and flare) was 
made. All bilastine doses inhibited the histamine-induced 
wheal between 1.5 and 12 hours and the flare between 4 and 
24 hours following administration, showing a response that 
is similar or better than cetirizine. No clear dose dependent 
effect was observed, although it was seen that the 20 and 
50 mg dose levels had a longer lasting effect.13
Audicana et al conducted a phase II study on 222 patients 
with chronic urticaria. The effect of bilastine (10, 20, and 
30 mg) was evaluated against a placebo in the control group 
for the appearance of papules and itching. Statistically 
significant differences were observed in the three treatment 
groups administered bilastine compared to the placebo group, 
although no dose dependent effect was observed, as reported 
by Ferrer et al.36
Bilastine was also assessed in a double blind controlled 
clinical trial with placebo and levocetirizine both administered 
for 28 days. A compound variable was evaluated by 
calculating the data for itching, number of wheals, and the 
maximum size of the wheals, based on patients’ diaries. The 
symptoms were reduced from the second day of treatment 
with 20 mg of bilastine, which was also the case for 
levocetirizine, showing better results than placebo.37
Tolerance and safety
In the various studies conducted during the preclinical 
development of bilastine, no signif icant toxicity was 
demonstrated. The acute toxicity of bilastine was investigated 
through the oral and intravenous administration in mice 
and rats. Following the oral administration of 5000 and 
2000 mg/kg in mice and rats respectively, no mortality was 
observed in either of the two species. However, following 
intravenous administration, the lethal dose for 50% of the 
animals was 33 mg/kg for mice and 45–75 mg/kg for rats.38
In chronic toxicity studies of bilastine administered both 
orally and intravenously, no signs of toxicity were observed 
in any organ.38 No effects on fertility, either on embryo-fetal 
toxicity or on teratogenicity, were observed in the studies 
conducted on mice and rabbits.39
When studies were conducted on humans during the 
assessment of the efficacy of bilastine in the treatment 
of chronic urticaria and allergic rhinitis, tolerability was 
studied in relation to a placebo and other antihistamines 
(levocetirizine, desloratadine, and cetirizine), and most of 
the data correspond to the therapeutic dose of 10 mg a day; 
Table 3 shows results of these clinical trials. Specific studies 
were also conducted to evaluate the incidence of problems 
commonly associated with the use of antihistamines, such 
as drowsiness and heart rate changes.
In general, bilastine was well tolerated and the majority 
of the adverse events described were either mild or moderate. 
The incidence of drug related adverse effects was 15%–30%, 
similar to observed with the placebo. There were no serious drug 
related adverse effects in any of the clinical trials. No significant 
changes were detected in vital signs (heart rate or blood pres-
sure), in the electrocardiogram (ECG) parameters or in labora-
tory values (hematology and liver and kidney function).29,30,37
The adverse events most commonly described by patients 
treated with bilastine and to some extent related to the drug, 
are: headache, drowsiness, dizziness, and fatigue.29,30,37,40 In 
a study in which the treatment was administered for 1-year, 
the most commonly described adverse effects were headache 
(9.6%) followed by nasopharyngitis (2.5%), while other less 
common bilastine related adverse effects included some 
changes in the ECG trace, which were not consistent over time.31
No differences were observed in the tolerance of bilastine 
compared to cetirizine and desloratadine.29,37 One study 
described a statistically significant minor incidence in the 
appearance of drowsiness, (bilastine and cetirizine, 1.8% 
versus 7.5%) and fatigue, (bilastine and cetirizine, 0.4% versus 
4.8%) with 20 mg a day of bilastine compared to cetirizine 
at normal dose levels.30
Some second generation antihistamines have been associ-
ated with adverse cardiac effects, such as the prolongation of 
the QT interval and the development of torsades de pointes. 
These effects have been attributed to the direct blocking of 
the potassium channels. For this reason, and following the 
guidelines of International Conference on Harmonisation 
(ICH) E14, a study was conducted to evaluate the effect of 
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the 20 mg therapeutic dose and that of a supratherapeutic 
dose of 100 mg on the QTc interval. This was a multidose 
randomized double blind crossover study with placebo and 
with 400 mg moxifloxacin, the latter an active comparator 
responsible for changes of this type. A fifth arm was included 
in which a 20 mg dose of bilastine in combination with the 
administration of 400 mg of ketoconazole. No effects with 
either 20 mg or 100 mg of bilastine were observed on the 
electrocardiogram trace, the QTc duration, or on the T wave 
morphology. The increase in the value of the ATc interval of 
5 milliseconds or less confirms this lack of influence. No sig-
nificant effects on the QTc interval were observed with any of 
the doses evaluated. The changes reported in the combination 
of bilastine with ketoconazole were related to the antifungal 
drug, given the fact that the plasma concentrations of bilas-
tine in this coadministration were less than those observed 
with the supratherapeutic dose of 100 mg.41,42 These results 
are consistent with other investigations on bilastine and in 
clinical trials with patients in which no changes in the electro-
cardiogram or cardiac related adverse effects were observed.
The evaluation of neurological tolerance was conducted 
with specif ic studies to evaluate the appearance of 
drowsiness/sedation and the effect on attention when 
driving a vehicle following bilastine treatment. The sedating 
effect of first generation antihistamines is widely known, 
which in some cases has led these drugs to be used as 
sleeping pills.43 This effect is related to the affinity for the 
P glycoprotein, which is responsible for the efflux of drugs 
and other substances from the central nervous system, and to 
drug lipophilicity; the greater the affinity and the lower the 
lipophilicity, the lower the blood-brain barrier crossing.
In a repeat dose crossover trial with healthy volunteers, 
three doses of bilastine (20, 40, and 80 mg) were compared 
to 25 mg of hydroxyzine and placebo following 7 days of 
treatment and with a washout period of 15 days between 
each scheduled administration. An evaluation was made 
of the effects on psychomotor function (motor activity, 
perception, attention, associative integration) and state of 
mind. Hydroxyzine caused an increase in the time to react, 
a decrease in the blinking rate, and a worsening of attention 
or motor activity. With the 20 and 40 mg doses of bilastine, no 
changes were observed in the parameters evaluated, although 
changes were observed with the highest dose (80 mg) when 
evaluating objective parameters. Subjectively, only the 20 mg 
dose was distinguishable from the placebo.3
A clinical trial was conducted with 22 healthy volunteers, 
who were administered daily doses of bilastine (20 mg and 
40 mg) for an 8-day period, and compared to a placebo and 
50 mg a day of hydroxyzine (positive control) to evaluate 
the effect of the drug on driving. This was a crossover study 
with a 7-day interval between treatment periods. The position 
of the car was evaluated at a constant speed, recording the 
deviation of the car in relation to the standard deviation of 
lateral position. No changes were observed with the 20 and 
Table 3 Bilastine tolerability determined during clinical investigation
Author Type of patients, number, 
and length of treatment
Bilastine tolerability Active comparator 
tolerability
Placebo tolerability
Bachert et al29 Seasonal allergic rhinitis (n = 721); 
14 days; bilastine 20 mg,  
desloratadine 5 mg, and placebo
21% 
Headache 12% 
Somnolence 3.9% 
Fatigue 2.6%
20% 
Headache 11.2% 
Somnolence 3.7% 
Fatigue 1.2%
19% 
Headache 10.2% 
Somnolence 2.4% 
Fatigue 2.4%
Kuna et al30 Seasonal allergic rhinitis (n = 681); 
14 days; bilastine 20 mg, 
cetirizine 10 mg, and placebo
14.5% 
Headache 10.6% 
Somnolence 1.8% 
Fatigue 0.4% 
Dyspnea 0.9%
24.6% 
Headache 8.3% 
Somnolence 7.5% 
Fatigue 4.8% 
Dyspnea 2.2%
19.5% 
Headache 13.7% 
Somnolence 2.2% 
Fatigue 3.1% 
Dyspnea 0.9%
Zuberbier et al37 Chronic idiopathic urticarial 
(n = 525); 28 days; bilastine 20 mg, 
levocetirizine 5 mg, and placebo
30.1% 
Headache 12.1% 
Somnolence 5.8% 
Fatigue 2.9%
26.7% 
Headache 12.1% 
Somnolence 6.7% 
–
22.8% 
Headache 9.2% 
Somnolence 3.3% 
Fatigue 2.7%
Sastre et al31 Perennial allergic rhinitis (n = 650); 
4 weeks; bilastine 20 mg, 
cetirizine 10 mg, and placebo
23.4% 
Headache 10.7% 
Somnolence 13.7%
19.8% 
Headache 5.1% 
Somnolence 6.9%
27.9% 
Headache 13.7% 
Somnolence 3.2%
Sastre et al31 Perennial allergic rhinitis (n = 513); 
1-year, bilastine 20 mg
31% 
Headache 9.6% 
Somnolence 1.4% 
Nasopharyngitis 2.5% 
QT wave prolongation 1.8%
– –
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40 mg doses of bilastine, providing results similar to the 
placebo, with evaluations made on the first and eighth day 
of treatment. With hydroxyzine, a significant increase was 
observed in the deviations for all measurements, although 
it was reduced in relation to the first administration, in a 
situation of pharmacokinetic balance, following the final 
dose.44
In the overall analysis of the data on the development of 
sleepiness observed in the different studies conducted with 
bilastine, it was concluded that its appearance is similar to 
that observed with a placebo, and significantly less than that 
observed with cetirizine.45
Further studies have been conducted to evaluate the effects 
of bilastine on the central nervous system in combination with 
other drugs such as lorazepam or substances such as alcohol, 
whose sedative effect is well known. None of these studies 
with 20 mg of bilastine produced such an effect, neither did 
they increase the effect produced by these known central 
nervous system depressants.18,19
Conclusion
Bilastine is a second generation antihistamine developed 
for the treatment of allergic rhinoconjunctivitis and chronic 
urticaria. It is a product that does not undergo hepatic 
metabolism nor does it modify the activity of the cytochrome 
P450 isoenzymes. It should not be administered at meal 
times, which may increase its bioavailability. Treatment 
with 20 mg, administered orally, is effective in controlling 
the symptoms and improving the quality of life of these 
patients. The studies conducted to date indicate that bilastine 
has an acceptable tolerability profile, given the fact that no 
cardiotoxic effects have been observed, and the therapeutic 
dose does not change a patient’s state of alertness.
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